Ge Longhui, January 29丨Guangzheng Ophthalmology (002524.SZ) announced the 2023 annual performance forecast. Operating income for the reporting period was 1060 million yuan to 1080 million yuan 767.4446 million yuan, up 38.12% to 40.73% over the same period of the previous year; net profit attributable to shareholders of listed companies was 8 million yuan to 12 million yuan, or -78.1776 million yuan in the same period last year; net profit after deducting non-recurring profit and loss was -4 million yuan to -2 million yuan, compared to -291.681 million yuan for the same period last year; basic per share Earnings of $0.02 to $0.03.
The main reason for the company's performance growth during the reporting period to reverse losses was: 1. In 2023, the domestic economy recovered overall, and the annual GDP growth rate recovered to more than 5%. The domestic consumer market gradually recovered after experiencing a complex environment in 2022. The company seizes the opportunities of the recovery in consumer demand and the increase in patients' demand for eye health, adheres to the patient-centered concept, solidly promotes discipline construction, continuously improves the level and quality of medical services, strengthens academic construction, and promotes collaborative development of medical education and research services. Overall performance has recovered rapidly. In particular, for diseases such as cataracts and fundus disease, the cumulative demand for diseases such as cataracts and fundus disease was released relatively centrally in 2023, leading to rapid growth in related businesses; revenue from refractive optometry diseases also increased year-on-year; the company's overall revenue grew steadily, driving up overall profits and achieving steady, moderate and positive business performance.
In 2023, the company leased some of its energy and steel structure assets, improving the efficiency of asset use and increasing profitability; the costs and expenses of newly opened hospitals and clinics in the big health sector increased relatively, but as ophthalmology revenue increased, overall profitability increased.